SecBot SecBot
PRESS-RELEASE ·Filed Nov 5, 2026

INO

Inovio Pharmaceuticals, Inc.
BEARISH
Impact 6/10
Horizonimmediate Processed11d 3h ago WireGlobeNewswire
Press release · Offering
Actionable Insight ▼ Bearish

The $75M raise extends cash runway but at severe dilution; monitor the underwriters' option exercise and the company's path to first commercial revenue from VOCERYQ. The 90-day lock-up may limit near-term selling pressure from insiders.

DirectionBearish
Confidencehigh
Horizonimmediate

Drug in focus

INO drug pipeline →

VOCERYQ

● Neutral Named in this press release
Impact
Phase
Approved (Accelerated Approval)
Time to market
Already approved (October 30, 2026). Commercial launch expected in Q1 2027, with initial ordering and shipping in approximately 60 days.
Next catalyst
None dated

What to watchWith the approval binary resolved, the next key events are the confirmatory study protocol submission (due end of 2026, final by mid-2027) and the commercial launch in Q1 2027. Monitor initial prescription uptake and payer coverage in the first two quarters post-launch, as Inovio's cash runway extends only into late Q1 2027, leaving little margin for a slow commercial start.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$1.22
T+0 close · Nov 5, 2026 · via day close
Latest settled
+17.70%
T+5 · $1.43
Vs SPY
+15.10%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $1.22entry
  2. T+1 · 8d ago +24.28%α +21.91% · $1.51
  3. T+5 · 4d ago +17.70%α +15.10% · $1.43
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Inovio priced a $75M underwritten public offering of 58.7M shares at $1.05/share plus pre-funded warrants, following the October 30 FDA accelerated approval of VOCERYQ (INO-3107) for RRP. The offering from the $300M shelf, underwritten by Jefferies and Piper Sandler, represents ~34% dilution based on shares outstanding before the offering, underscoring ongoing capital needs for a pre-revenue biotech with a going concern warning.

Key Financial Metrics

Deal Value
$75.0M

Key Facts

  • Priced 58,747,235 shares at $1.05/share and 12,681,337 pre-funded warrants at $1.049 each
  • Gross proceeds expected ~$75M before underwriting discounts and commissions
  • Underwriters have 30-day option to purchase up to 10,714,285 additional shares
  • Offering expected to close on or about November 9, 2026
  • Jefferies and Piper Sandler are joint book-running managers; H.C. Wainwright is lead manager
  • Offering follows October 30, 2026 FDA accelerated approval of VOCERYQ (INO-3107) for RRP
  • Preliminary Q3 2026 cash balance was $48.4M with a going concern warning
  • 90-day lock-up for company and insiders per the 424B5 filing

Financial Impact

$75M gross proceeds from offering; dilution of ~34% based on shares outstanding before the offering (58.7M new shares vs ~172M pre-offering, plus warrants)

dilutioncashshare count

Risk Factors

  • Dilution of ~34% from the offering, with additional overhang from the underwriters' option
  • Going concern warning remains despite the capital raise; pre-revenue status with only one approved product
  • Market conditions could worsen, making future capital raises more difficult or expensive
  • The offering was priced at $1.05, below the prior day's close (not stated, but typical discount for at-the-market offerings)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
71% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-prn-302931699

Track record

20 reports on INO

Performance horizon

8 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +46.23% at T+20 after the Jul 2, 2026 report. 9 of 14 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.39 Now $1.40 +0.72% settles Nov 24
  2. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $1.40 Now $1.40 −0.01% settles Nov 24
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.41 Now $1.40 −0.71% settles Nov 23
  4. Nov 10, 20266d ago 8-K Bearish 5/10 Entry $1.48 Now $1.40 +5.08% settles Nov 18
  5. Nov 9, 20267d ago 8-K Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
  6. Nov 6, 202610d ago 424B5 Bearish 5/10 Entry $1.51 to $1.40 Now $1.40 +7.28% ▲ +7.28% +5.59% vs SPY
  7. Nov 5, 202611d ago Press Release Bearish 6/10 Viewing Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  8. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  9. Nov 5, 202611d ago 424B5 Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
  10. Nov 5, 202611d ago Press Release Bearish 4/10 Entry $1.22 to $1.43 Now $1.40 −15.23% ▼ −17.70% −15.10% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026